FL-101 + nivolumab

FL-101 + nivolumab is a combination therapy being investigated for **neoadjuvant treatment in surgically resectable non-small cell lung cancer (NSCLC)**. FL-101 is an investigational agent; the specific modality or molecular target of FL-101 is not stated in public sources, but it is being developed and studied as both monotherapy and in combination with the approved immune checkpoint inhibitor **nivolumab**. Nivolumab is a **monoclonal antibody targeting the immune checkpoint receptor programmed death-1 (PD-1)** on T cells, which blocks inhibitory signaling to restore anti-tumor immunity. In the combination regimen, both FL-101 and nivolumab are administered intravenously before surgery to assess whether they can improve major pathological response rates when used together. This approach is under clinical investigation in Phase 2 studies for resectable NSCLC[1][3][6].

Other names

FL-101FL101FL 101Opdivo